Brought to you by 
Abbott enters mitral valve replacement market via $250mm Tendyne buy
09 Sep 2020
Executive Summary
Abbott Laboratories Inc. acquired the portion of private device company Tendyne Holdings Inc. (minimally invasive mitral valve replacement therapies) that it doesn’t already own, paying $225mm in cash up front, and a potential $25mm in earn-outs contingent on regulatory milestones.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott enters mitral valve replacement market via $250mm Tendyne buy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice